Skip to Main Content

Paper Details

Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
Eur J Cancer
5
2022
Author NameAffiliation
Cora N SternbergEnglander Institute for Precision Medicine, Sandra and Edward Meyer Cancer Center, USA Presbyterian Hospital
  • 1 - 1

Datasets

Release 1.2